Max Rosett
CIK: 0001994071
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Immunome Inc.
Discretionary Trading P&L
Holdings
Transaction History (10 total)
- Jul 23, 2026IMNM
Immunome Inc.
Award(A)Direct47.3K shares- - Jun 15, 2026IMNM
Immunome Inc.
Exercise(M)Direct60K shares at avg. $1.05$63K - Jun 15, 2026IMNM
Immunome Inc.
Sale(S)Direct60K shares at avg. $18.23$1.1M - Apr 2, 2026IMNM
Immunome Inc.
Sale(S)Direct1.3K shares at avg. $22.48$30K - Apr 2, 2026IMNM
Immunome Inc.
Sale(S)Direct63.7K shares at avg. $21.91$1.4M - Apr 2, 2026IMNM
Immunome Inc.
Exercise(M)Direct31.8K shares at avg. $1.05$33K - Apr 2, 2026IMNM
Immunome Inc.
Exercise(M)Direct39.7K shares at avg. $1.35$54K - Jul 29, 2025IMNM
Immunome Inc.
Award(A)DirectEmployee Stock Option (right to buy)
207K shares- - Sep 19, 2024IMNM
Immunome Inc.
Exercise(M)Direct42K shares at avg. $1.05$44K - Sep 19, 2024IMNM
Immunome Inc.
Sale(S)Direct14.4K shares at avg. $16.01$230K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 23, 2026 | IMNM Immunome Inc. | Award(A) | 47,250 | - | $0 | Direct |
| Jun 15, 2026 | IMNM Immunome Inc. | Exercise(M) | 60,000 | $1.05 | $63,000 | Direct |
| Jun 15, 2026 | IMNM Immunome Inc. | Sale(S) | 60,000 | $18.23 | $1,093,800 | Direct |
| Apr 2, 2026 | IMNM Immunome Inc. | Sale(S) | 1,344 | $22.48 | $30,213 | Direct |
| Apr 2, 2026 | IMNM Immunome Inc. | Sale(S) | 63,656 | $21.91 | $1,394,703 | Direct |
| Apr 2, 2026 | IMNM Immunome Inc. | Exercise(M) | 31,848 | $1.05 | $33,440 | Direct |
| Apr 2, 2026 | IMNM Immunome Inc. | Exercise(M) | 39,713 | $1.35 | $53,613 | Direct |
| Jul 29, 2025 | IMNM Immunome Inc. | Award(A) Employee Stock Option (right to buy) | 207,000 | - | - | Direct |
| Sep 19, 2024 | IMNM Immunome Inc. | Exercise(M) | 42,000 | $1.05 | $44,100 | Direct |
| Sep 19, 2024 | IMNM Immunome Inc. | Sale(S) | 14,380 | $16.01 | $230,224 | Direct |
1-10 of 10 transactions
About Rosett Max
Rosett Max (SEC CIK 0001994071) files insider reports with the SEC as Chief Financial Officer of Immunome Inc. (IMNM).
Signal8 holds 5 ownership filings by Rosett Max, all Form 4s, filed between Sep 20, 2024 and Jul 27, 2026. Those filings report 10 transactions, from Sep 19, 2024 to Jul 23, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Rosett Max's filings is in BOTHELL, WA.
Recent filings by Rosett Max
- Jul 23, 2026: Grant or award of IMNM shares (Form 4, code A).
- Jun 15, 2026: Option exercise of IMNM shares (Form 4, code M).
- Jun 15, 2026: Open-market sale of IMNM shares (Form 4, code S).
- Apr 2, 2026: Open-market sales of IMNM shares (2 lines, Form 4, code S).
- Apr 2, 2026: Option exercises of IMNM shares (2 lines, Form 4, code M).
Other insiders filing for Immunome Inc. (IMNM)
- Higgins Jack, Chief Scientific Officer
- Barchas Isaac, Director
- Horn Kinney, CHIEF BUSINESS OFFICER
- Tsai Philip, Chief Technical Officer
- Stoneman Sandra G., CHIEF LEGAL OFFICER & GC
- Lechleider Robert, Chief Medical Officer